Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Non-Current Deffered Revenue (2021 - 2022)

Senti Biosciences has reported Non-Current Deffered Revenue over the past 2 years, most recently at $7.0 million for Q1 2022.

  • Quarterly results put Non-Current Deffered Revenue at $7.0 million for Q1 2022, changed N/A from a year ago — trailing twelve months through Mar 2022 was $7.0 million (changed N/A YoY), and the annual figure for FY2021 was $176000.0, changed.
  • Non-Current Deffered Revenue for Q1 2022 was $7.0 million at Senti Biosciences, up from $176000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for SNTI hit a ceiling of $8.0 million in Q2 2021 and a floor of $176000.0 in Q4 2021.